Technology | June 01, 2008

Molecular Imaging Agents Created for In Vivo, In Vitro Applications

Carestream expanded its line of imaging agents with Kodak X-Sight Nanosphere Conjugates labeled with Streptavidin for both in vivo and in vitro applications, aiming to provide an effective means for life science researchers to detect biotinylated probes in fluorescent molecular biology research applications.

The new conjugates labeled with Streptavidin will be offered in four distinct wavelengths from ultraviolet (UV) to near infrared (near IR). They are designed to provide an incredibly bright platform for translating molecular imaging experiments from in vitroto in vivoapplications.

The Kodak X-Sight imaging agent family also includes KODAKX SIGHT Nanospheres and KODAKX-SIGHT Large Stokes Shift Dyes, which are also offered in a variety of conjugated forms. While the KODAKX-SIGHT Imaging Agents have been optimized for KODAK In-Vivo Imaging Systems and KODAK Image Stations, they are compatible with other commercially available digital imaging systems.

Kodak X-SightNanosphere Conjugates labeled with Streptavidin will be available in July.

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init